Modified release dosage form

• US 8,673,352 B2
• Filed: 04/15/2005
• Issued: 03/18/2014
• Est. Priority Date: 04/15/2005
• Status: Active Grant

• Current Assignee: Johnson & Johnson Consumer Inc. (Johnson & Johnson)
• Original Assignee: McNeil-PPC Incorporated (Johnson & Johnson)
• Inventors: Sowden, Harry S.
• Primary Examiner(s): BARHAM, BETHANY P
• Application Number:
  US11/107,674
• Publication Number:
  US 20060233881A1
• Time in Patent Office: 3,259 Days
• Field of Search: None
• US Class Current: 424/464
• CPC Class Codes: A61K 9/2022 Organic macromolecular compounds
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• CPC Class Codes: A61K 9/2072 characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms A61K9/0004, A61K9/0056, A61K9/0065 take precedence
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to a medicinal dosage form having a first core, a second core, and a shell that surrounds a first portion of each core and a fill material that covers a second portion of at least one core, wherein the fill material that is provided over at least one core is not in contact with any portion of the other core. e. The inventive dosage forms provide modified release of one or more active ingredients contained therein. The present invention also relates to methods for manufacturing such medicinal dosage forms.

Claims

1. A medicinal dosage form comprising:

a first core and a second core,

wherein said first core comprises a first active ingredient and said second core comprises a second active ingredient,

wherein said first core and said second core each have a diameter of at least about 6.35 millimeters, respectively, and

a shell that is provided over and having a surface conforming or defining a first portion of said first core and a first portion of said second core,

a first fill material provided over and having a surface conforming to or defining a second portion of said first core,

wherein the first fill material does not overlap with the shell along the circumference of the core, wherein said fill material covers said second portion of said first core and said second portion of said second core exclusively and does not cover said first portion of said first core or said first portion of said second core,

wherein the first active ingredient is released through the first fill material, and wherein the first active ingredient is not released through the shell, and

a second fill material provided over and having a surface conforming to or defining a second portion of said second core,

wherein the second fill material does not overlap with the shell along the circumference of the core,

wherein the second active ingredient is released through the second fill material, and

wherein the second active ingredient is not released through the shell;

wherein the first fill material in contact with said first core is not in contact with any portion of said second core,

wherein the second fill material in contact with said second core is not in contact with any portion of said first core,

wherein the first fill material provides for immediate release of the first active ingredient,

wherein the second fill material provides for delayed, sustained, prolonged, extended, pH-dependent, or retarded release of the second active ingredient,

wherein said first core and said second core are each selected from the group consisting of a tablet, a capsule, a suppository, a confectionery, a semi-solid in finished dosage form and a liquid in finished dosage form.

2. A dosage form according to claim 1, wherein the first fill material and the second fill material are each substantially devoid of pores having a diameter of 0.5 to 5.0 microns.

3. A dosage form according to claim 1, wherein the first fill material, the second fill material and the shell are substantially devoid of pores having a diameter of 0.5 to 5.0 microns.

4. A dosage form according to claim 1, wherein the first fill material, the second fill material or both the first fill material and the second fill material extends above the surface level of the shell.

5. A dosage form according to claim 1, wherein the dosage form further comprises a third core that has a first portion having a shell material that has been provided over and with a surface conforming thereto or defining a recess therein and a second portion that has been provided with a fill material with a surface conforming thereto.

6. A dosage form according to claim 1, wherein the shell is substantially free of pores having a diameter of 0.5 to 5.0 microns.

7. A dosage form according to claim 1, wherein the shell provides for delayed, sustained, prolonged, extended, or retarded release of at least one active ingredient contained in the second core.

8. A dosage form according to claim 1, wherein the shell comprises at least one material that is insoluble, semi-permeable, pH-dependent, or erodible in an aqueous environment.

9. A dosage form according to claim 1, wherein the second fill material comprises material that is insoluble, semi-permeable, pH-dependent, or erodible in a liquid medium to provide said delayed release of active.

10. A dosage form according to claim 1, wherein a plurality of beads containing a pharmaceutically active ingredient are formed as a core within a defined recess of the shell.